Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A wake‐up call to quiescent cancer cells – potential use of DYRK1B inhibitors in cancer therapy
Walter Becker
FEBS Journal (2017) Vol. 285, Iss. 7, pp. 1203-1211
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer
Galia Maik-Rachline, Avital Hacohen-Lev-Ran, Rony Seger
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1194-1194
Open Access | Times Cited: 188
Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Damilohun Samuel Metibemu, Oluseyi Adeboye Akinloye, Adio Jamiu Akamo, et al.
Egyptian Journal of Medical Human Genetics (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 113
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
Mattias F. Lindberg, Laurent Meijer
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 6047-6047
Open Access | Times Cited: 81
Causal interactions from proteomic profiles: Molecular data meet pathway knowledge
Özgün Babur, Augustin Luna, Anil Korkut, et al.
Patterns (2021) Vol. 2, Iss. 6, pp. 100257-100257
Open Access | Times Cited: 75
The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities
Jacopo Boni, Carlota Rubio-Pérez, Núria López-Bigas, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2106-2106
Open Access | Times Cited: 74
The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target
Malini Rammohan, Ethan Harris, Rahul S. Bhansali, et al.
Oncogene (2022) Vol. 41, Iss. 14, pp. 2003-2011
Open Access | Times Cited: 38
Quiescent Cancer Cells—A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse
Emma Lindell, Lei Zhong, Xiaonan Zhang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3762-3762
Open Access | Times Cited: 29
Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis
Graeme J. Koelwyn, Joseph Pierre Aboumsallem, Kathryn J. Moore, et al.
Journal of Molecular and Cellular Cardiology (2021) Vol. 163, pp. 1-8
Open Access | Times Cited: 54
Serum deprivation initiates adaptation and survival to oxidative stress in prostate cancer cells
Elshaddai White, Nakea M. Pennant, Jada R. Carter, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 52
DREAM On: Cell Cycle Control in Development and Disease
Hayley C Walston, Audra N. Iness, Larisa Litovchick
Annual Review of Genetics (2021) Vol. 55, Iss. 1, pp. 309-329
Open Access | Times Cited: 37
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
Lee Walmsley, James B. Murray, P. Dokurno, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8971-8991
Closed Access | Times Cited: 33
Molecular Mechanisms Governing the Stem Cell’s Fate in Brain Cancer: Factors of Stemness and Quiescence
Valeriia Gulaia, Vadim Kumeiko, Nikita A. Shved, et al.
Frontiers in Cellular Neuroscience (2018) Vol. 12
Open Access | Times Cited: 40
Advances in therapeutic agents targeting quiescent cancer cells
Wan Najbah Nik Nabil, Zhichao Xi, Mengfan Liu, et al.
Acta Materia Medica (2022) Vol. 1, Iss. 1
Open Access | Times Cited: 21
A safe haven for cancer cells: tumor plus stroma control by DYRK1B
Miriam Ems, Anna Brichkina, Matthias Lauth
Oncogene (2025)
Open Access
Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin
Chao Dong, Kirk L. West, Xin Yi Tan, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 29, pp. 17019-17030
Open Access | Times Cited: 29
Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy
Nikolaos Kokkorakis, Marios Zouridakis, Maria Gaitanou
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 528-528
Open Access | Times Cited: 3
MuvB: A Key to Cell Cycle Control in Ovarian Cancer
Audra N. Iness, Larisa Litovchick
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 28
DYRK1B inhibition exerts senolytic effects on endothelial cells and rescues endothelial dysfunctions
Francesca Michela Pramotton, Asra Abukar, Chantelle Hudson, et al.
Mechanisms of Ageing and Development (2023) Vol. 213, pp. 111836-111836
Open Access | Times Cited: 8
The histone chaperone complex FACT promotes proliferative switch of G 0 cancer cells
Ling Bi, Chanlu Xie, Yao Mu, et al.
International Journal of Cancer (2018) Vol. 145, Iss. 1, pp. 164-178
Open Access | Times Cited: 26
Research progress on therapeutic targeting of quiescent cancer cells
Jinhua Zhang, Jing Si, Lu Gan, et al.
Artificial Cells Nanomedicine and Biotechnology (2019) Vol. 47, Iss. 1, pp. 2810-2819
Open Access | Times Cited: 25
Targeting DYRK1A/B kinases to modulate p21‐cyclin D1‐p27 signalling and induce anti‐tumour activity in a model of human glioblastoma
Andrew J. Massey, Karen Benwell, Mike F. Burbridge, et al.
Journal of Cellular and Molecular Medicine (2021) Vol. 25, Iss. 22, pp. 10650-10662
Open Access | Times Cited: 17
Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models
Laura J. Mauro, Megan Seibel, Caroline H. Diep, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 106, Iss. 7, pp. 1929-1955
Open Access | Times Cited: 16
Mirk/Dyrk1B controls ventral spinal cord development via Shh pathway
Nikolaos Kokkorakis, Katerina Douka, A. Nalmpanti, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 2
Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B
Gerrit Wilms, Kevin Schofield, Shayna Maddern, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
A Bioinformatics Evaluation of the Role of Dual-Specificity Tyrosine-Regulated Kinases in Colorectal Cancer
Amina Jamal Laham, Raafat El‐Awady, Jean‐Jacques Lebrun, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 2034-2034
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top